MX2013005182A - Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr. - Google Patents
Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.Info
- Publication number
- MX2013005182A MX2013005182A MX2013005182A MX2013005182A MX2013005182A MX 2013005182 A MX2013005182 A MX 2013005182A MX 2013005182 A MX2013005182 A MX 2013005182A MX 2013005182 A MX2013005182 A MX 2013005182A MX 2013005182 A MX2013005182 A MX 2013005182A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- egfr
- treatment
- agents
- family members
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
El uso de los compuestos de la fórmula (I): ( Ver Formula) en el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidérmico (EGFR) o de las enfermedades que hayan adquirido resistencia a los agentes que tengan como objetivo los miembros de la familia de los receptores del factor de crecimiento epidérmico (EGFR), el uso de estos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento de estas enfermedades, combinaciones de estos compuestos con moduladores de los receptores del factor de crecimiento epidérmico (EGFR) para dicho uso, los métodos para el tratamiento de estas enfermedades con tales compuestos, y las preparaciones farmacéuticas que comprenden estos compuestos para el tratamiento de dichas enfermedades, solos o en combinación, en especial con un modulador de los receptores del factor de crecimiento epidérmico (EGFR).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41111710P | 2010-11-08 | 2010-11-08 | |
PCT/EP2011/069522 WO2012062694A1 (en) | 2010-11-08 | 2011-11-07 | Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013005182A true MX2013005182A (es) | 2013-07-03 |
MX360157B MX360157B (es) | 2018-10-24 |
Family
ID=44947083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005182A MX360157B (es) | 2010-11-08 | 2011-11-07 | Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr. |
Country Status (12)
Country | Link |
---|---|
US (4) | US20130209461A1 (es) |
EP (1) | EP2637661B1 (es) |
JP (4) | JP2013542228A (es) |
KR (1) | KR101854484B1 (es) |
CN (2) | CN103200943A (es) |
AU (1) | AU2011328227B2 (es) |
BR (1) | BR112013009624A2 (es) |
CA (1) | CA2815492C (es) |
MX (1) | MX360157B (es) |
RU (1) | RU2589695C2 (es) |
TR (1) | TR201802943T4 (es) |
WO (1) | WO2012062694A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2017119219A (ru) * | 2011-10-14 | 2018-11-02 | Новартис Аг | 2-карбоксамид циклоамино производные мочевины в комбинации с ингибиторами hsp90 для лечения пролиферативных заболеваний |
US20140302022A1 (en) * | 2011-11-02 | 2014-10-09 | Novartis Ag | 2-carboxamide clycloamino urea derivatives for use in treating vegf-dependent diseases |
EA028420B1 (ru) * | 2012-08-07 | 2017-11-30 | Новартис Аг | Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа |
RU2705095C2 (ru) * | 2012-08-16 | 2019-11-05 | Новартис Аг | Комбинация ингибитора pik3 и ингибитора с-мет |
MX2015014063A (es) * | 2013-04-05 | 2015-12-11 | Sanofi Sa | Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa. |
JP2016539149A (ja) | 2013-12-06 | 2016-12-15 | ノバルティス アーゲー | アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
KR20100093129A (ko) * | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Pi 3 키나제 억제제로서 사용되는 티아졸 유도체 |
AR070865A1 (es) * | 2008-03-18 | 2010-05-12 | Genentech Inc | Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
-
2011
- 2011-11-07 US US13/879,644 patent/US20130209461A1/en not_active Abandoned
- 2011-11-07 TR TR2018/02943T patent/TR201802943T4/tr unknown
- 2011-11-07 AU AU2011328227A patent/AU2011328227B2/en active Active
- 2011-11-07 EP EP11782111.6A patent/EP2637661B1/en active Active
- 2011-11-07 BR BR112013009624A patent/BR112013009624A2/pt not_active IP Right Cessation
- 2011-11-07 KR KR1020137011803A patent/KR101854484B1/ko active IP Right Grant
- 2011-11-07 CN CN2011800538729A patent/CN103200943A/zh active Pending
- 2011-11-07 CA CA2815492A patent/CA2815492C/en active Active
- 2011-11-07 CN CN201510770643.9A patent/CN105412105A/zh active Pending
- 2011-11-07 JP JP2013537156A patent/JP2013542228A/ja active Pending
- 2011-11-07 RU RU2013126485/15A patent/RU2589695C2/ru active
- 2011-11-07 MX MX2013005182A patent/MX360157B/es active IP Right Grant
- 2011-11-07 WO PCT/EP2011/069522 patent/WO2012062694A1/en active Application Filing
-
2015
- 2015-05-26 US US14/721,064 patent/US20150250778A1/en not_active Abandoned
-
2016
- 2016-07-07 JP JP2016134705A patent/JP2016222686A/ja not_active Withdrawn
-
2018
- 2018-07-12 US US16/033,764 patent/US20180325883A1/en not_active Abandoned
- 2018-10-24 JP JP2018199647A patent/JP2019048822A/ja not_active Withdrawn
-
2019
- 2019-09-17 US US16/573,909 patent/US20200022967A1/en not_active Abandoned
-
2020
- 2020-03-26 JP JP2020056250A patent/JP2020114849A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20150250778A1 (en) | 2015-09-10 |
WO2012062694A1 (en) | 2012-05-18 |
TR201802943T4 (tr) | 2018-03-21 |
JP2020114849A (ja) | 2020-07-30 |
JP2016222686A (ja) | 2016-12-28 |
US20200022967A1 (en) | 2020-01-23 |
RU2013126485A (ru) | 2014-12-20 |
US20130209461A1 (en) | 2013-08-15 |
EP2637661A1 (en) | 2013-09-18 |
CA2815492C (en) | 2019-04-09 |
JP2013542228A (ja) | 2013-11-21 |
CN105412105A (zh) | 2016-03-23 |
AU2011328227A1 (en) | 2013-04-18 |
CA2815492A1 (en) | 2012-05-18 |
JP2019048822A (ja) | 2019-03-28 |
KR20130143582A (ko) | 2013-12-31 |
AU2011328227B2 (en) | 2015-04-09 |
US20180325883A1 (en) | 2018-11-15 |
EP2637661B1 (en) | 2017-12-20 |
KR101854484B1 (ko) | 2018-05-03 |
RU2589695C2 (ru) | 2016-07-10 |
CN103200943A (zh) | 2013-07-10 |
BR112013009624A2 (pt) | 2016-07-12 |
MX360157B (es) | 2018-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010009743A (es) | Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami | |
AU2018260809A1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
PH12016500372A1 (en) | Pharmaceutical composition containing pyrimidine compound as active ingredient | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
MY191087A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
MX2015011769A (es) | Compuestos y sus usos para modular la hemoglobina. | |
MX2015011509A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
EP2571357A4 (en) | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINAS MODULATION | |
EA201491617A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
HUE043540T2 (hu) | Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben | |
EA201590855A1 (ru) | Соединения пирролопиримидина как ингибиторы киназ | |
MX368346B (es) | Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas. | |
MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
MX360157B (es) | Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr. | |
EA201370018A1 (ru) | Составы рифаксимина и их применение | |
IL228600A0 (en) | (Aralkylamino and heteroarylalkylamino alpha-converted) pyrimidinyl and 1,3,5-triazinyl benzaimidazoles, pharmaceutical compounds containing them and use of these compounds in the treatment of proliferative diseases | |
SG10201805552PA (en) | Sodium channel modulators for the treatment of pain and diabetes | |
MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
WO2014110353A9 (en) | Notch ligand bound biocompatible substrates and their use in bone formation | |
TW201613578A (en) | Pharmaceutical combinations | |
EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |